IL20 and rheumatoid arthritis: The anti-IL-20 antibody was well tolerated and showed no safety issues in healthy volunteers and patients with rheumatoid arthritis [65], which demonstrated the safety of anti-IL-20 as a new therapeutic drug for DED.